Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study

The Journal of Dermatology
Esra AdişenMehmet Ali Gürer

Abstract

Although the mechanisms underlying the loss of response to infliximab are not completely understood, the formation of antibodies to infliximab (ATI) are thought to play a role. The aim of this study was to investigate the presence of ATI in psoriatic patients and to evaluate its relationship to the clinical response. Fifteen patients with psoriasis were treated with infliximab (5 mg/kg) every 8 weeks after an initial three-dose induction treatment. An enzyme linked immunosorbent assay kit was used for analyzing the presence of ATI in sera. Effectiveness assessments included the change in Psoriasis Area and Severity Index (PASI) compared with study entry. Five (33.3%) patients developed ATI. While 5.9 +/- 3.2 infliximab infusions achieved a fall in the PASI score from a mean of 20.4 +/- 8.3 to 5.3 +/- 2.4 in ATI-negative patients, these values changed from 23.3 +/- 11 to 10 +/- 4.9 after 9 +/- 5.2 infusions in ATI-positive patients. Our results suggested that ATI measured in psoriatic patients are of clinical importance. Therefore, monitoring for the induction of ATI and rescue strategies should be developed to avoid or to maintain a delay in ATI development.

References

Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Jun 6, 2003·Journal of the American Academy of Dermatology·Alice B GottliebDaniel G Baker
Nov 25, 2003·Cancer Biotherapy & Radiopharmaceuticals·Andres ForeroAlbert F LoBuglio
Feb 6, 2004·Gastroenterology·Paul RutgeertsStephen B Hanauer
Apr 21, 2004·Journal of Pediatric Gastroenterology and Nutrition·Erasmo MieleRobert N Baldassano
Jun 30, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Stephen B HanauerPaul Rutgeerts
Sep 25, 2004·Journal of the American Academy of Dermatology·Alice B GottliebAlan Menter
May 3, 2007·Annals of the Rheumatic Diseases·Mirjam K de VriesIrene E van der Horst-Bruinsma
Jul 11, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Alexander NastUNKNOWN Berufsverband Deutscher Dermatologen (BVDD)

❮ Previous
Next ❯

Citations

Sep 6, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Marina PapoutsakiAntonio Costanzo
Jan 12, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Daiju IwataSusumu Ishida
Dec 4, 2012·Journal of Crohn's & Colitis·Martin BortlikMilan Lukas
Sep 30, 2015·The Journal of Dermatological Treatment·Michel de la BrassinneFabienne Willaert
Apr 30, 2013·Actas dermo-sifiliográficas·J M Carrascosa
Aug 14, 2015·Rheumatology·Thierry SchaeverbekeChristophe Richez
May 11, 2012·Annales de dermatologie et de vénéréologie·D Jullien
Aug 15, 2014·The Journal of Investigative Dermatology·Denis JullienFrank O Nestle
Oct 15, 2013·The British Journal of Dermatology·L HsuA W Armstrong
May 21, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·J-M CarrascosaJ C Prinz
May 13, 2015·American Journal of Clinical Dermatology·Michael E Farhangian, Steven R Feldman
Jan 24, 2015·International Journal of Clinical Pharmacy·L ElberdínI Martín
Apr 6, 2017·Therapeutic Drug Monitoring·Caroline HermansAnn Gils
Mar 25, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·K M HoeglerR A Schwartz
Sep 7, 2013·Pediatric Gastroenterology, Hepatology & Nutrition·Yun Seok LeeYon Ho Choe
Oct 6, 2018·Dermatologic Therapy·Agnieszka Owczarczyk-SaczonekAdriana Rakowska
Nov 17, 2014·The Journal of Rheumatology·Michael ZisapelOri Elkayam
Oct 17, 2013·Expert Review of Clinical Immunology·Leeyen Hsu, April W Armstrong
Jun 11, 2019·Journal of Immunotoxicology·Shunsuke ItoChiyomi Kubo
Nov 8, 2019·The Journal of Dermatological Treatment·M Colls-GonzalezN Padullés-Zamora
Jan 9, 2021·Frontiers in Immunology·Sinem Nihal EsatogluGulen Hatemi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.